Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in cytokine-refractory metastatic renal cell carcinoma
NCT00077974Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2004
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in renal cell carcinoma (RCC), sponsored by Pfizer. Primary endpoint: Objective Response Rate. Started Feb 2004; status: completed.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00077974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077974.